Cytokinetics (CYTK) Total Non-Current Liabilities (2016 - 2026)
Cytokinetics (CYTK) posted quarterly Total Non-Current Liabilities of $2.1 billion for Q1 2026, up 36.32% year-over-year from $1.5 billion in Q1 2025, and up 0.85% quarter-over-quarter from $2.1 billion in Q4 2025.
Cytokinetics (CYTK) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Total Non-Current Liabilities for 11 consecutive years, with $2.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 36.32% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 36.32% YoY), while the FY2025 annual figure was $2.1 billion, up 34.56% from the prior year.
- Total Non-Current Liabilities grew to $2.1 billion in Q1 2026 per CYTK's latest filing, from $2.1 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.1 billion in Q1 2026 and bottomed at $658.9 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 170.16% — and 2024, when it gained 6.59%.
- Cytokinetics' Total Non-Current Liabilities stood at $1.1 billion in 2022, then rose by 6.81% to $1.2 billion in 2023, then gained by 27.35% to $1.5 billion in 2024, then surged by 34.56% to $2.1 billion in 2025, then increased by 0.85% to $2.1 billion in 2026.
- Business Quant data shows CYTK's Total Non-Current Liabilities at $2.1 billion in Q1 2026, $2.1 billion in Q4 2025, and $2.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 2.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.07 Bn |
| Mar 31, 2026 | 2.07 Bn |
| Dec 31, 2025 | 2.05 Bn |
| Sep 30, 2025 | 1.96 Bn |
| Jun 30, 2025 | 1.58 Bn |
| Mar 31, 2025 | 1.52 Bn |
| Dec 31, 2024 | 1.53 Bn |
| Sep 30, 2024 | 1.45 Bn |
| Jun 30, 2024 | 1.31 Bn |
| Mar 31, 2024 | 1.19 Bn |
| Dec 31, 2023 | 1.20 Bn |
| Sep 30, 2023 | 1.18 Bn |
| Jun 30, 2023 | 1.11 Bn |
| Mar 31, 2023 | 1.12 Bn |
| Dec 31, 2022 | 1.12 Bn |
| Sep 30, 2022 | 1.09 Bn |
| Jun 30, 2022 | 658.86 Mn |
| Mar 31, 2022 | 736.78 Mn |
| Dec 31, 2021 | 593.00 Mn |
| Sep 30, 2021 | 403.72 Mn |